News stories about Entellus Medical (NASDAQ:ENTL) have been trending somewhat positive on Saturday, Accern reports. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Entellus Medical earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave news articles about the medical technology company an impact score of 46.0565441637067 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
A number of research analysts have commented on the company. Zacks Investment Research cut Entellus Medical from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. BidaskClub cut Entellus Medical from a “sell” rating to a “strong sell” rating in a research note on Saturday, February 17th. TheStreet upgraded Entellus Medical from a “d” rating to a “c-” rating in a research note on Thursday, December 14th. Finally, William Blair cut Entellus Medical from an “outperform” rating to a “market perform” rating in a research note on Friday, December 8th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $20.33.
NASDAQ:ENTL remained flat at $$24.00 during trading hours on Friday. The company has a quick ratio of 1.71, a current ratio of 1.92 and a debt-to-equity ratio of 0.32. Entellus Medical has a fifty-two week low of $11.47 and a fifty-two week high of $25.58.
WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Entellus Medical (ENTL) Stock Price” was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3338390/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-entellus-medical-entl-stock-price.html.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.